Co-Diagnostics Inc
Company Profile
Business description
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Contact
2401 South Foothill Drive
Salt Lake CityUT84109
USAT: +1 801 438-1036
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
132
Stocks News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
stocks
Does this bank have what it takes to compete with the big 4?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.80 | 20.30 | -0.23% |
| CAC 40 | 8,085.23 | 23.20 | -0.29% |
| DAX 40 | 24,155.96 | 109.95 | 0.46% |
| Dow JONES (US) | 47,739.32 | 215.67 | -0.45% |
| FTSE 100 | 9,648.28 | 3.19 | 0.03% |
| HKSE | 25,434.23 | 331.13 | -1.29% |
| NASDAQ | 23,545.90 | 32.22 | -0.14% |
| Nikkei 225 | 50,655.10 | 73.16 | 0.14% |
| NZX 50 Index | 13,454.78 | 31.54 | -0.23% |
| S&P 500 | 6,846.51 | 23.89 | -0.35% |
| S&P/ASX 200 | 8,585.90 | 20.50 | -0.24% |
| SSE Composite Index | 3,909.52 | 14.56 | -0.37% |